|
Physiomics PLC on Tuesday reported the signing of a new contract, as it looks to accelerate the development of a ‘promising’ drug programme. The Oxfordshire, England-based mathematical modelling company said it has inked an 18-month contract worth £98,600 with an existing, unnamed client that will see it apply PK/PD modelling and simulation expertise ‘to support preclinical-to-clinical translation for one of the client’s lead candidates’. Physiomics said it will inform selection of human dosing schemes for a first in human clinical trial. It added that the contract ‘highlights the value of Physiomics’ integrated modelling and simulation approach across the drug development lifecycle.’ Shares in Physiomics were 2.7% lower at 0.45 pence on Tuesday afternoon in London. Chief Executive Peter Sargent said: ‘We are delighted to continue partnering with this client and announce this follow on work with their team. Working with them from early discovery through to clinical planning enables us to add deeper insights into their experimental and clinical trial design, helping them accelerate this promising drug development programme.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
